查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1963957

酵素结合免疫吸附 ）检测法市场 - 全球产业规模、份额、趋势、机会、预测：按类型、应用、最终用户、地区和竞争格局划分，2021-2031年

Enzyme Linked Immunosorbent Assay Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Type, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球酵素结合免疫吸附检测法(ELISA) 市场预计将从 2025 年的 37.9 亿美元成长到 2031 年的 60.8 亿美元，复合年增长率为 8.21%。

酵素连结免疫吸附试验 (ELISA) 是一种广泛应用的基于微孔板的分析技术，用于检测和测量生物样本中的可溶性物质，例如抗体、抗原、蛋白质和荷尔蒙。市场成长的主要驱动力是全球慢性疾病和感染疾病负担的日益加重，这些疾病和感染需要频繁且准确的诊断检测才能有效管理。此外，这些检测方法在药物发现和开发过程中的广泛应用也显着推动了市场需求。根据国际糖尿病联盟 (IDF) 预测，到 2024 年，全球将有约 5.89 亿成年人患有糖尿病，凸显了可靠的生物标记分析和持续健康监测解决方案的紧迫性。

市场概览
预测期 2027-2031
市场规模：2025年 37.9亿美元
市场规模：2031年 60.8亿美元
复合年增长率：2026-2031年 8.21%
成长最快的细分市场 夹心ELISA
最大的市场 北美洲

然而，诸如聚合酵素链锁反应(PCR) 和分子诊断等先进替代诊断技术的普及，凭藉其更高的灵敏度和更快的检测速度，对该市场构成了重大挑战。这些先进平台的激烈竞争可能会促使医疗机构优先考虑速度和准确性，从而限制传统免疫检测在某些高精度临床领域的应用。

市场驱动因素

慢性病和感染疾病的蔓延是全球酵素结合免疫吸附检测法(ELISA) 市场的主要驱动力。这是因为 ELISA 被认为是识别特定抗体和抗原的黄金标准，需要严格的诊断通讯协定。感染疾病病原体带来的沉重负担使得频繁检测成为必要，以确保有效的疾病管理和控制。例如，世界卫生组织 (WHO) 于 2024 年 10 月发布的《2024 年世界结核病报告》估计，2023 年全球将有 1,080 万人感染结核病，凸显了准确进行传染病筛检的重要性。此外，慢性病也对市场需求产生了显着影响。美国癌症协会于 2024 年 1 月发布的《2024 年癌症事实与数据》报告预测，2024 年美国新增癌症病例数将首次超过 200 万例，这表明对使用成熟免疫检测系统进行可靠的肿瘤标记分析的需求日益增长。

同时，生物製药研发和药物发现倡议的不断拓展是市场成长的关键驱动力。製药公司在整个药物开发过程中高度依赖酵素连结免疫吸附试验（ELISA），例如免疫抗原性测试、药物动力学研究以及生物製药的毒性筛检。随着业界专注于开发新型疗法，对研发基础设施的投资不断增加，直接导致试剂和检测试剂盒的消耗量上升。根据罗氏于2024年3月发布的《2023年度报告》，该集团的核心研发投资达到132亿瑞士法郎，这笔巨额投资推动了对高精度生物分析仪器的需求。对药物发现领域的持续资本投入确保了对高灵敏度诊断检测的持续需求。

市场挑战

全球酵素结合免疫吸附检测法(ELISA) 市场扩张的主要障碍是来自先进诊断技术的日益激烈的竞争，尤其是聚合酵素链锁反应(PCR) 和分子诊断技术。与传统的基于微孔板的免疫检测相比，这些替代系统能够提供更快的检测速度和更高的灵敏度。因此，在需要即时做出临床决策和高精度检测的情况下，例如基因分析和传染病检查，检查室和医疗机构越来越倾向于采用这些先进方法。这一趋势有效地阻碍了 ELISA 试剂盒在对准确性和速度要求极高的领域的应用，从而降低了其在高价值临床市场中的潜在份额。

近期产业趋势凸显了竞争平台的涌现，也印证了这场技术变革的规模。根据美国临床实验室医师协会 (ASCL) 统计，2024 年临床实验室博览会吸引了约 900 家参展，清楚地表明了该行业正向自动化和先进分子技术转型。商业性关注和创新集中于尖端替代技术，凸显了市场动态。随着医疗系统和製造商将资源集中于更灵敏、更快速的诊断工具，传统酵素连结免疫检测的需求持续承压，阻碍了这一关键诊断领域的成长。

市场趋势

自动化高通量ELISA工作站的日益普及正在改变检查室的工作流程，以满足对可重复性和操作效率的迫切需求。面对不断增长的检体量，生物分析检查室和诊断中心正果断地摒弃人工操作，转向采用全整合机器人系统，从而降低人事费用和人为误差。这种转变在免疫诊断领域尤其显着，自动化能够在确保准确性的同时，快速处理复杂的检测。根据Revvity于2025年2月发布的2024年度报告，该公司诊断业务收入达15.09亿美元，其中免疫诊断业务收入增长4370万美元，成为收入增长的关键驱动力，也显示市场对先进自动化解决方案的强劲需求。

同时，由于传统模拟方法难以检测低浓度生物标记物，市场正加速向单分子检测技术和超灵敏数位ELISA的转型。这项技术创新使临床医生和研究人员能够以飞克级定量蛋白质，为肿瘤学和神经病学等领域的疾病早期检测创造了新的机会。随着临床疗效的检验和普及程度的提高，向这些新一代平台的过渡正在加速。正如RTTNews在2025年11月报导的《Quanterix公司第三季亏损超出预期》所述，该公司宣布第三季营收达4,023万美元，较去年同期成长12.3%，显示数位生物标记检测系统的商业性发展势头强劲。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：酵素结合免疫吸附检测法的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依类型（直接ELISA、间接ELISA、夹心ELISA）
    • 按应用领域（疾病诊断、疫苗研发等）
    • 依最终使用者（医院、研究机构、学术机构）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美酵素结合免疫吸附检测法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲酵素结合免疫吸附检测法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区酵素结合免疫吸附市场检测法

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲酵素结合免疫吸附市场检测法

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲酵素结合免疫吸附市场检测法

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球酵素结合免疫吸附检测法：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Thermo Fisher Scientific Inc
  • Bio-Rad Laboratories, Inc
  • Agilent Technologies, Inc
  • Merck KGaA
  • Promega Corporation
  • Neogen Corporation
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • Becton, Dickinson and Company
  • BioMerieux SA

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 24325

The Global Enzyme Linked Immunosorbent Assay Market is projected to expand from USD 3.79 Billion in 2025 to USD 6.08 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 8.21%. ELISA is a widely utilized plate-based analytical method designed to detect and measure soluble substances, including antibodies, antigens, proteins, and hormones, within biological samples. The market's growth is primarily fueled by the increasing global burden of chronic and infectious diseases, which demands frequent and precise diagnostic testing for effective management. Furthermore, the growing application of these assays in drug discovery and development processes significantly strengthens demand. According to the International Diabetes Federation, there were roughly 589 million adults living with diabetes globally in 2024, emphasizing the urgent need for dependable biomarker analysis and ongoing health monitoring solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.79 Billion
Market Size 2031USD 6.08 Billion
CAGR 2026-20318.21%
Fastest Growing SegmentSandwich ELISA
Largest MarketNorth America

However, the market faces a substantial obstacle regarding the availability of advanced alternative diagnostic technologies, such as polymerase chain reaction (PCR) and molecular diagnostics, which frequently provide superior sensitivity and more rapid turnaround times. The fierce competition presented by these sophisticated platforms potentially restricts the usage of traditional immunoassays within specific high-precision clinical sectors, as healthcare providers may favor newer methods for their speed and accuracy.

Market Driver

The escalating prevalence of chronic and infectious diseases acts as a major engine for the Global Enzyme Linked Immunosorbent Assay Market, necessitating rigorous diagnostic protocols where ELISA serves as the gold standard for identifying specific antibodies and antigens. The significant burden of infectious pathogens necessitates high testing volumes to ensure effective disease control and management. For instance, the World Health Organization's 'Global Tuberculosis Report 2024', released in October 2024, estimated that 10.8 million individuals contracted tuberculosis worldwide in 2023, underlining the vital need for precise infectious disease screening. Additionally, chronic diseases heavily influence market demand; the American Cancer Society's 'Cancer Facts & Figures 2024' report from January 2024 projected that the United States would exceed 2 million new cancer cases for the first time in 2024, highlighting the increasing requirement for reliable tumor marker analysis via established immunoassay systems.

Concurrently, the broadening scope of biopharmaceutical R&D and drug discovery initiatives is a significant propeller of market growth. Pharmaceutical firms rely heavily on ELISA throughout the drug development pipeline for tasks such as immunogenicity testing, pharmacokinetic studies, and toxicity screening of biologics. As the industry sharpens its focus on developing novel therapeutics, investment in research infrastructure has escalated, leading to a direct rise in the consumption of reagents and assay kits. According to Roche's 'Annual Report 2023' published in March 2024, the group's core research and development investments climbed to CHF 13.2 billion, demonstrating the substantial financial commitment that fuels the demand for high-precision bioanalytical instruments. This sustained capital allocation towards discovery ensures a continuous requirement for sensitive diagnostic assays.

Market Challenge

The principal impediment to the expansion of the Global Enzyme Linked Immunosorbent Assay (ELISA) Market is the mounting competition from advanced diagnostic technologies, specifically polymerase chain reaction (PCR) and molecular diagnostics. These alternative systems provide faster turnaround times and enhanced sensitivity compared to conventional plate-based immunoassays. As a result, laboratories and healthcare providers are increasingly preferring these advanced methods for scenarios demanding immediate clinical decisions and high precision, such as genetic analysis and infectious disease testing. This trend effectively curtails the uptake of ELISA kits in sectors where accuracy and speed are critical, thereby reducing their potential share in high-value clinical markets.

The scale of this technological shift is evident in recent industry activities that emphasize these competing platforms. According to the Association for Diagnostics & Laboratory Medicine, the 2024 Clinical Lab Expo featured nearly 900 exhibitors, clearly highlighting the industry's transition toward automated and advanced molecular technologies. This aggregation of commercial focus and innovation on sophisticated alternatives accentuates the shifting market dynamics. As healthcare systems and manufacturers increasingly direct resources toward these more sensitive and rapid diagnostic tools, the demand for traditional enzyme-linked assays encounters persistent pressure, hindering their growth in vital diagnostic areas.

Market Trends

The increasing integration of automated high-throughput ELISA workstations is transforming laboratory workflows by meeting the urgent need for reproducibility and operational efficiency. Facing rising sample volumes, bioanalytical laboratories and diagnostic centers are decisively moving away from manual plate handling in favor of fully integrated robotic systems that reduce labor costs and human error. This shift is especially prominent in the immunodiagnostics field, where automation facilitates the swift processing of complex assays while maintaining precision. According to Revvity's 'Annual Report for Fiscal Year 2024' from February 2025, the company reported diagnostics segment revenue of $1,500.9 million, bolstered significantly by a $43.7 million rise in immunodiagnostics revenue, signaling strong demand for advanced automated solutions.

At the same time, the market is undergoing a major shift toward single-molecule detection technologies and ultrasensitive digital ELISA, spurred by the need to detect low-abundance biomarkers that conventional analog methods miss. This technological advancement enables clinicians and researchers to quantify proteins at femtogram levels, creating new opportunities for early disease detection in fields like oncology and neurology. The transition to these next-generation platforms is gaining speed as they become more clinically validated and accessible. As noted by RTTNews in November 2025 regarding the 'Quanterix Corp Q3 Loss Increases, Misses Estimates' report, Quanterix announced a 12.3% year-over-year revenue increase to $40.23 million for the third quarter, highlighting the increasing commercial momentum of its digital biomarker detection systems.

Key Market Players

  • Thermo Fisher Scientific Inc
  • Bio-Rad Laboratories, Inc
  • Agilent Technologies, Inc
  • Merck KGaA
  • Promega Corporation
  • Neogen Corporation
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • Becton, Dickinson and Company
  • BioMerieux SA

Report Scope

In this report, the Global Enzyme Linked Immunosorbent Assay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Enzyme Linked Immunosorbent Assay Market, By Type

  • Direct ELISA
  • Indirect ELISA
  • Sandwich ELISA

Enzyme Linked Immunosorbent Assay Market, By Application

  • Disease diagnosis
  • Vaccine Development
  • Other

Enzyme Linked Immunosorbent Assay Market, By End User

  • Hospitals
  • Research & Academic Institutions

Enzyme Linked Immunosorbent Assay Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Enzyme Linked Immunosorbent Assay Market.

Available Customizations:

Global Enzyme Linked Immunosorbent Assay Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Enzyme Linked Immunosorbent Assay Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Direct ELISA, Indirect ELISA, Sandwich ELISA)
    • 5.2.2. By Application (Disease diagnosis, Vaccine Development, Other)
    • 5.2.3. By End User (Hospitals, Research & Academic Institutions)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Enzyme Linked Immunosorbent Assay Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Enzyme Linked Immunosorbent Assay Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Enzyme Linked Immunosorbent Assay Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Enzyme Linked Immunosorbent Assay Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Enzyme Linked Immunosorbent Assay Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Enzyme Linked Immunosorbent Assay Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. France Enzyme Linked Immunosorbent Assay Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Enzyme Linked Immunosorbent Assay Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Enzyme Linked Immunosorbent Assay Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Enzyme Linked Immunosorbent Assay Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia Pacific Enzyme Linked Immunosorbent Assay Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Enzyme Linked Immunosorbent Assay Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Enzyme Linked Immunosorbent Assay Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Enzyme Linked Immunosorbent Assay Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Enzyme Linked Immunosorbent Assay Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Enzyme Linked Immunosorbent Assay Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. Middle East & Africa Enzyme Linked Immunosorbent Assay Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Enzyme Linked Immunosorbent Assay Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Enzyme Linked Immunosorbent Assay Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Enzyme Linked Immunosorbent Assay Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. South America Enzyme Linked Immunosorbent Assay Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Enzyme Linked Immunosorbent Assay Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Enzyme Linked Immunosorbent Assay Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Enzyme Linked Immunosorbent Assay Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Enzyme Linked Immunosorbent Assay Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bio-Rad Laboratories, Inc
  • 15.3. Agilent Technologies, Inc
  • 15.4. Merck KGaA
  • 15.5. Promega Corporation
  • 15.6. Neogen Corporation
  • 15.7. F. Hoffmann-La Roche Ltd
  • 15.8. Siemens Healthineers AG
  • 15.9. Becton, Dickinson and Company
  • 15.10. BioMerieux SA

16. Strategic Recommendations

17. About Us & Disclaimer